The macrolide clarithromycin inhibits experimental post-transplant bronchiolitis obliterans

Experimental Lung Research

Volumn 35, Issue 10, 2009, Pages 830-840

  Remund, K ^a   Rechsteiner, T ^a   Guo, Z ^a   Rentsch, K ^a   Boehler, A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Azithromycin; Bronchiolitis obliterans; Clarithromycin; Lung transplantation; Macrolide

Indexed keywords

CLARITHROMYCIN; GAMMA INTERFERON; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BRONCHIOLITIS OBLITERANS; CONTROLLED STUDY; DRUG ELIMINATION; DRUG INHIBITION; HUMAN; IMMUNOMODULATION; LUNG TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; BRONCHIOLITIS OBLITERANS; CLARITHROMYCIN; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; MATRIX METALLOPROTEINASE 2; RATS; RATS, INBRED BN; RATS, INBRED LEW; TRACHEA; TRANSPLANTATION, HETEROTOPIC; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 72049126633     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902140902918755     Document Type: Article

References (31)

1. Shinkai M, Henke MO, Rubin BK: Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther. 2008;117:393-405.
2. Knower MT, Labella-Walker K, McFadden PM, Kantrow SP, Valentine VG: Clarithromycin for safe and cost-effective reduction of cyclosporine doses in lung allograft recipients. South Med J. 2000;93:1087-1092.
3. Westphal JF: Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol. 2000;50:285-295.
4. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB: Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med. 2003;168:121-125.
5. Crowley S, Egan JJ: Macrolide antibiotics and bronchiolitis obliterans following lung transplantation. Expert Rev Anti Infect Ther. 2005;3:923-930.
6. Fietta AM, Meloni F: Lung transplantation: the role of azithromycin in the management of patients with bronchiolitis obliterans syndrome. Curr Med Chem. 2008;15:716-723.
7. Jain R, Danziger LH: The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des. 2004;10:3045-3053.
8. Shinkai M, Foster GH, Rubin BK: Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2006;290:L75-L85.
9. Tsai WC, Rodriguez ML, Young KS, Deng JC, Thannickal VJ, Tateda K, Hershenson MB, Standiford TJ: Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med. 2004;170:1331-1339.
10. Khan AA, Slifer TR, Araujo FG, Remington JS: Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents. 1999;11:121-132.
11. Bosnar M, Kelneríc Z, Muníc V, Erakovíc V, ParnhamMJ: Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob Agents Chemother. 2005;49:2372-2377.
12. Vanaudenaerde BM, Wuyts WA, Geudens N, Dupont LJ, Schoofs K, Smeets S, Van Raemdonck DE, Verleden GM: Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am J Transplant. 2007;7:76-82.
13. Murphy DM, Forrest IA, Corris PA, Johnson GE, Small T, Jones D, Fisher AJ, Egan JJ, Cawston TE, Lordan JL, Ward C: Azithromycin attenuates effects of lipopolysaccharide on lung allograft bronchial epithelial cells. J Heart Lung Transplant. 2008;27:1210-1216.
14. Boehler A, Chamberlain D, Kesten S, Slutsky AS, LiuM, Keshavjee S: Lymphocytic airway infiltration as a precursor to fibrous obliteration in a rat model of bronchiolitis obliterans. Transplantation 1997;64:311-317.
15. Remund K, Rechsteiner T, Rentsch K, Vogt P, Russi EW, Boehler A: Attenuation of airway obliteration by ciprofloxacin in experimental posttransplant bronchiolitis obliterans. Transplantation 2008;85:726-731.
16. Leonard S, Ferraro M, Adams E, Hoogmartens J, Van Schepdael A: Application of liquid chromatography/ ion trap mass spectrometry to the characterization of the related substances of clarithromycin. Rapid Commun Mass Spectrom. 2006;20:3101-3110. (Pubitemid 44569790)
17. Zhu W, Downey JS, Gu J, Di Padova F, Gram H, Han J: Regulation of TNF expression by multiple mitogen-activated protein kinase pathways. J Immunol. 2000;164:6349-6358.
18. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE: Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006;174:566-570.
19. Vanaudenaerde BM, Meyts I, Vos R, Geudens N, De Wever W, Verbeken EK, Van Raemdonck DE, Dupont LJ, Verleden GM: A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J. 2008;32:832-843.
20. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T: Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008;85:36-41.
21. Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR, Devera ME, Liang X, T̈or M, Billiar T: The grateful dead: damage-associated molecular pattern molecules and reduction/ oxidation regulate immunity. Immunol Rev. 2007;220:60-81.
22. Barton GM: A calculated response: control of inflammation by the innate immune system. J Clin Invest. 2008;118:413-420.
23. Medzhitov R: Recognition of microorganisms and activation of the immune response. Nature 2007;449:819-826.
24. Egerton M, Fitzpatrick DR, Kelso A: Activation of the extracellular signal-regulated kinase pathway is differentially required for TCR-stimulated production of six cytokines in primary T lymphocytes. Int Immunol. 1998;10:223-229.
25. Murphy DM, Forrest IA, Ward C, Corris PA, Johnson GE, Jones D, Fisher AJ, Egan JJ, Cawston TE, Lordan JL: Effect of azithromycin on primary bronchial epithelial cells derived from stable lung allografts. Thorax. 2007;62:834.
26. Armstrong DA, Major JA, Chudyk A, Hamilton TA: Neutrophil chemoattractant genes KC and MIP-2 are expressed in different cell populations at sites of surgical injury. J Leukoc Biol. 2004;75:641-648.
27. Boehler A, Bai XH, Liu M, Cassivi S, Chamberlain D, Slutsky AS, Keshavjee S: Upregulation of T-helper 1 cytokines and chemokine expression in post-transplant airway obliteration. Am J Respir Crit Care Med. 1999;159:1910-1917.
28. Vrevik J, Lag M, Schwarze P, Refsnes M: p38 and Src-ERK1/2 pathways regulate crystalline silicainduced chemokine release in pulmonary epithelial cells. Toxicol Sci. 2004;81:480-490.
29. Ghosh AK, Varga J: The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J Cell Physiol. 2007;213:663-671.
30. Caraci F, Gili E, Calafiore M, Failla M, La Rosa C, Crimi N, Sortino MA, Nicoletti F, Copani A, Vancheri C: TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol Res. 2008;57:274-282.
31. Kim KD, Zhao J, Auh S, Yang X, Du P, Tang H, Fu YX: Adaptive immune cells temper initial innate responses. Nat Med. 2007;13:1248-1552.